These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34934970)

  • 41. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Salminen JK; Kuoppamäki V; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
    Int J Cancer; 2021 Jul; 149(2):307-315. PubMed ID: 33634851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
    Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
    Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
    Tan XL; E JY; Lin Y; Rebbeck TR; Lu SE; Shang M; Kelly WK; D'Amico A; Stein MN; Zhang L; Jang TL; Kim IY; Demissie K; Ferrari A; Lu-Yao G
    Cancer Med; 2020 Apr; 9(7):2379-2389. PubMed ID: 32035002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
    Danzig MR; Kotamarti S; Ghandour RA; Rothberg MB; Dubow BP; Benson MC; Badani KK; McKiernan JM
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):63-8. PubMed ID: 25403419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
    Winters B; Plymate S; Zeliadt SB; Holt S; Zhang X; Hu E; Lin DW; Morrissey C; Wooldridge B; Gore JL; Porter MP; Wright JL
    Prostate; 2015 Nov; 75(15):1694-703. PubMed ID: 26201966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
    Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
    Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
    Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
    BMC Cancer; 2020 Jun; 20(1):551. PubMed ID: 32539807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation.
    Seikkula H; Boström PJ; Seppä K; Pitkäniemi J; Malila N; Kaipia A
    BMC Urol; 2020 Mar; 20(1):25. PubMed ID: 32164671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Si S; Zheng B; Wang Z; Niu Z
    Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
    James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
    Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
    Nordström T; Clements M; Karlsson R; Adolfsson J; Grönberg H
    Eur J Cancer; 2015 Apr; 51(6):725-33. PubMed ID: 25727881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.
    Goldberg H; Mohsin FK; Berlin A; Chandrasekar T; Wallis CJD; Klaassen Z; Ahmad AE; Saskin R; Kenk M; Saarela O; Kulkarni GS; Alibhai SMH; Fleshner N
    Urol Oncol; 2021 Mar; 39(3):191.e17-191.e24. PubMed ID: 32951988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
    Heidenreich A; Pfister D; Brehmer B; Porres D
    Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.